- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors
An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2a Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Therapeutic Activity of GI-102 in Patients With Advanced or Metastatic Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase 1/2a, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, and anti-tumor effect of GI-102 as a single agent over a range of advanced and/or metastatic solid tumors. This study is adaptive in nature. While GI-102 is being investigated as a single agent in this trial, GI-102 has the potential of being combined with other agents. Based on the data from ongoing nonclinical studies and the dose escalation phase, additional combination therapies [GI-102 + drug(s) X] may be proposed and added to this study protocol via an amendment.
This study will comprise two phases.
- GI-102 monotherapy dose escalation phase
- GI-102 monotherapy dose expansion phase
GI-102 is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety configurated via a human immunoglobulin G4 (IgG4) Fc. GI-102 has unique characteristics by having bispecificity to CD80 and IL2Rβγ. The CD80 portion is responsible for targeting tumor/immune cells while blocking CTLA-4 expressed on the Treg cells. The IL-2v of GI-102 is designed to abolish IL-2Rα affinity and therefore minimize the effect on Treg while it has very outstanding effect on NK and CD8 T cell proliferation and activity through IL-2Rbr affinity.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Woosun Lee
- Phone Number: +82-2-404-2003
- Email: Clinical-102@gi-innovation.com
Study Contact Backup
- Name: Jay Kim
- Phone Number: +82-2-404-2003
- Email: Clinical-102@gi-innovation.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital
-
Contact:
- Seock-Ah Im, M.D., Ph.D.
-
Seoul, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center
-
Contact:
- Jae Lyun Lee, M.D., Ph.D.
-
Principal Investigator:
- Jae Lyun Lee, M.D., Ph.D.
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Principal Investigator:
- Jeeyun Lee, M.D., Ph.D.
-
Contact:
- Jeeyun Lee, M.D., Ph.D.
-
Seoul, Korea, Republic of, 03722
- Recruiting
- Yonsei University Health System, Severance Hospital
-
Contact:
- Jung-Yun Lee, M.D., Ph.D.
-
Principal Investigator:
- Jung-Yun Lee, M.D., Ph.D.
-
Suwon, Korea, Republic of, 12647
- Recruiting
- St. Vincent's Hospital
-
Contact:
- Byoung Yong Shim, M.D., Ph.D.
-
-
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Recruiting
- Mayo Clinic in Arizona
-
Contact:
- Mahesh Seetharam
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Recruiting
- Mayo Clinic in Florida
-
Contact:
- Yujie Zhao
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Minnesota
-
Contact:
- Jian Li Campian, PhD.
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
Contact:
- Wen Wee Ma, M.B.B.S
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
- Has adequate organ and marrow function as defined in protocol.
- Measurable disease as per RECIST v1.1.
- ECOG performance status 0-1.
- Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy.
- HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol.
Key Exclusion Criteria:
- Has known active CNS metastases and/or carcinomatous meningitis.
- An active second malignancy.
- Has active or a known history of Hepatitis B or known active Hepatitis C virus infection.
- Has active tuberculosis or has a known history of active tuberculosis.
- Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.
- History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis.
- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- Previous immunotherapies related to mode of action of GI-102.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day 1.
- Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
- Radiotherapy within the last 2 weeks before start of study treatment administration, with exception of limited field palliative radiotherapy.
- Administration of a live, attenuated vaccine within 4 weeks before Cycle 1 Day 1.
- Known hypersensitivity to any of the components of the drug products and/or excipients of GI-102.
Other protocol defined inclusion exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose escalation phase : GI-102 as a single agent
Dose escalation: GI-102, multiple ascending doses
|
Dose escalation phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles). Dose expansion phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles). |
Experimental: Dose expansion phase : GI-102 as a single agent
Dose expansion: GI-102, tentative RP2D
|
Dose escalation phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles). Dose expansion phase: GI-102 will be administered via IV infusion Q3W up to 2 years (approximately 35 cycles). |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase)
Time Frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
|
A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.
|
Study Day 1, assessed up to DLT period (3 weeks after treatment)
|
Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Preexisting conditions which worsen during a study are also considered as AEs.
All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
Study Day 1, assessed up to approximately 24 months
|
Objective Response Rate (ORR) (dose expansion phase)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR).
PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
|
Study Day 1, assessed up to approximately 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose expansion phase)
Time Frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
|
A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.
|
Study Day 1, assessed up to DLT period (3 weeks after treatment)
|
Objective Response Rate (ORR) (dose escalation phase)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR).
PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
|
Study Day 1, assessed up to approximately 24 months
|
Disease Control Rate (DCR)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
DCR is defined as the percentage of patients who have achieved CR, PR and stable disease (SD), per RECIST v1.1 guideline as determined by the investigators.
|
Study Day 1, assessed up to approximately 24 months
|
Duration of objective response (DoR)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
DCR is defined as the time from the first occurrence of a documented objective response to the time of the first document disease progression or death from any cause, whichever occurs first, per RECIST v1.1 as determined by the investigator.
|
Study Day 1, assessed up to approximately 24 months
|
Progression-free survival (PFS)
Time Frame: 6-month, 12-month, and 18-month
|
PFS is defined as the time from the first study treatment (Day 1) to the first occurrence of progression or death from any cause, whichever occurs first, per RECIST v1.1 guideline as determined by the investigator
|
6-month, 12-month, and 18-month
|
Overall survival (OS)
Time Frame: 12-month and 18-month
|
OS is defined as the time from the first study treatment to death from any cause
|
12-month and 18-month
|
Peak plasma concentration (Cmax) of GI-102
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Based on the concentration vs time profile by dose level
|
Study Day 1, assessed up to approximately 24 months
|
Half-life of GI-102 (T1/2)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Based on the concentration vs time profile by dose level
|
Study Day 1, assessed up to approximately 24 months
|
Area under the plasma concentration versus time curve (AUC) of GI-102
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Based on the concentration vs time profile by dose level
|
Study Day 1, assessed up to approximately 24 months
|
Clearance of GI-102
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Based on the concentration vs time profile by dose level
|
Study Day 1, assessed up to approximately 24 months
|
Volume of distribution (Vd) of GI-102 after administration
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Based on the concentration vs time profile by dose level
|
Study Day 1, assessed up to approximately 24 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of anti-GI-102 antibody (ADA) and neutralizing antibody (Nab)
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Serum will be assessed for the presence of ADA and Nab based on the appropriate assay.
|
Study Day 1, assessed up to approximately 24 months
|
Immunophenotyping of peripheral blood CD4+ T cells
Time Frame: Study Day 1, assessed up to approximately 24 months
|
CD4+ T cells in peripheral blood will be assessed by flow cytometry at various time points
|
Study Day 1, assessed up to approximately 24 months
|
Immunophenotyping of peripheral blood CD8+ T cells
Time Frame: Study Day 1, assessed up to approximately 24 months
|
CD8+ T cells in peripheral blood will be assessed by flow cytometry at various time points
|
Study Day 1, assessed up to approximately 24 months
|
Immunophenotyping of peripheral blood Treg cells
Time Frame: Study Day 1, assessed up to approximately 24 months
|
Treg cells in peripheral blood will be assessed by flow cytometry at various time points
|
Study Day 1, assessed up to approximately 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Nari Yun, PhD, GI Innovation, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GII-102-P101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on GI-102
-
Maastricht University Medical CenterCompleted
-
NestléClinical Nutrition Research Centre, SingaporeCompleted
-
Temple UniversityInternational Life Sciences InstituteCompleted
-
GI DynamicsCompleted
-
Ohio State UniversityRecruitingGlucose Metabolism Disorders | Spinal Cord Injuries | Postprandial HypotensionUnited States
-
Federal University of VicosaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Amparo...CompletedType 2 Diabetes MellitusBrazil
-
Kirstine Nyvold Bojsen-MoellerUniversity of CopenhagenCompleted
-
Maastricht University Medical CenterUnilever R&DCompletedObesity | Diet, Healthy | Fatty Liver, NonalcoholicNetherlands
-
Research Institute of Child Nutrition, DortmundUnknownCognitive FunctionGermany
-
Beth Israel Deaconess Medical CenterBoston Children's Hospital; Brigham and Women's HospitalCompleted